Company Announcement no. 25/2010
To: NASDAQ OMX Copenhagen A/S Hørsholm,
Denmark, November 25, 2010
LifeCycle Pharma A/S - Major Shareholder Announcement
LifeCycle Pharma A/S (OMX: LCP) has received a major shareholder notice, that
Novo A/S has increased its holdings of shares/voting rights in LifeCycle Pharma
A/S from 13,404,663 shares/voting rights to 120,184,740 shares/voting rights,
corresponding to an increase from 23.7 % of the total number of shares/voting
rights in LifeCycle Pharma A/S to 26.6 % of the total number of shares/voting
rights in LifeCycle Pharma A/S.
For more information, please contact:
LifeCycle Pharma A/S
William J. Polvino, President and CEO Johnny Stilou, CFO
Mobile: +1 917 647 9107 Mobile: +45 20 55 38 52
Email: WJP@lcpharma.com Email: JST@lcpharma.com
Forward-looking statement disclaimer
This press release contains certain forward-looking statements, including
statements about the Company's business and its shares. Such forward-looking
statements are based on data, assumptions and estimates that the Company
considers to be reasonable. They are subject to numerous risks and
uncertainties, including matters not yet known to the Company or not currently
considered material by the Company, and there can be no assurance that
anticipated events will occur or that the objectives set out will actually be
achieved. Important factors that could cause actual results to differ
materially from the results anticipated in forward-looking statements include,
among others, market conditions and the price of the Company's shares,
completion of and the actual outcome of the Company's ongoing Phase III
clinical studies of LCP-Tacro™, as well as changes in pharmaceutical industry
regulation and, in particular, regulatory approval of pharmaceutical drugs, as
well as the other risk factors the Company has included in its public
disclosures.
